ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUPH vs PVLA // DIVIDEND YIELD & FCF PAYOUT SAFETY

Aurinia Pharmaceuticals Inc (NASDAQ) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AUPH 4 — PVLA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. PVLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUPH PVLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 16.50% -27.90% +44.40 AUPH /roic <GO>
EV/EBITDA & P/E Valuation 21.1x — — TIE /valuation <GO>
Free Cash Flow Yield 5.92% -1.14% +7.06 AUPH /fcf-yield <GO>
Operating Margin 37.10% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 20.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.33 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 AUPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 57.6 -8.50 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.22B $2.11B $109.5M AUPH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUPH REV PVLA REV AUPH GROSS % PVLA GROSS % AUPH FCF PVLA FCF
FY 2025 $283.1M $108.1M 88.5% — $135.7M -$25.0M
FY 2024 $235.1M $39.5M 88.0% — $44.4M -$10.8M
FY 2023 $175.5M $42.8M — — -$33.5M -$13.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
PVLA // BETA —